アブストラクト
| Title | (1) 食道癌薬物療法の最前線 |
|---|---|
| Subtitle | 特集 消化器癌の薬物治療 up-to-date |
| Authors | 下嵜啓太郎, 中山厳馬, 高張大亮 |
| Authors (kana) | |
| Organization | がん研究会有明病院消化器化学療法科 |
| Journal | 消化器クリニカルアップデート |
| Volume | 3 |
| Number | 1 |
| Page | 10-15 |
| Year/Month | 2021 / 11 |
| Article | 報告 |
| Publisher | 医学図書出版 |
| Abstract | 「要旨」食道癌では, 周術期化学療法や根治的化学放射線, さらには緩和的化学療法など, それぞれのステージにおいて化学療法が重要な役割を果たしてきた. 他癌腫での華々しい治療開発を追うように, 近年食道癌においても免疫チェックポイント阻害剤の有効性が検証された. さらには長らく変わらなかった切除不能進行再発例に対する1次治療についても, 免疫チェックポイント阻害剤と化学療法の併用療法が有効性を示し, 食道癌治療は新たなステージを迎えていると言える. |
| Practice | 臨床医学：内科系 |
| Keywords | 薬物療法, 免疫チェックポイント阻害剤, 集学的治療, Esophageal cancer, Chemotherapy, Immune checkpoint inhibitor |
- 全文ダウンロード： 従量制、基本料金制の方共に1,023円(税込) です。
参考文献
- 1) Kato H, Sato A, Fukuda H, et al:A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma:Japan Clinical Oncolo-gy Group Study(JCOG9708). Jpn J Clin Oncol 39:638-643,2009
- 2) Kato K, Igaki H, Ito Y, et al:Parallel-group con-trolled trial of esophagectomy versus chemora-diotherapy in patients with clinical stage I esophageal carcinoma(JCOG0502). J Clin Oncol 37:7,2019
- 3) Ando N, Kato H, Igaki H, et al:A randomized trial comparing postoperative adjuvant chemo-therapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized ad-vanced squamous cell carcinoma of the thoracic esophagus(JCOG9907). Ann Surg Oncol 19:68-74,2012
- 4) Kato K, Muro K, Minashi K, et al:Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma:JCOG trial(JCOG 9906). Int J Radiat Oncol Biol Phys 81:684-690,2011
- 5) Yokota T, Kato K, Hamamoto Y, et al:Phase II study of chemoselection with docetaxel plus cis-platin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer 115:1328-1334,2016
残りの12件を表示する
- 6) Terada M, Hara H, Daiko H, et al:Phase III study of tri-modality combination therapy with induc-tion docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus(JCOG1510:TRIAN-gLE). Jpn J Clin Oncol 49:1055-1060,2019
- 7) Iizuka T, Kakegawa T, Ide H, et al:Phase II evaluation of cisplatin and 5-fluorouracil in ad-vanced squamous cell carcinoma of the esopha-gus:a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22:172-176,1992
- 8) Hayashi K, Ando N, Watanabe H, et al:Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carci-noma of the esophagus:a Japan Esophageal On-cology Group(JEOG)Trial(JCOG9407). Jpn J Clin Oncol 31:419-423,2001
- 9) Kato K, Sun JM, Shah MA, et al:LBA8_PR Pem-brolizumab plus chemotherapy versus chemo-therapy as first-line therapy in patients with ad-vanced esophageal cancer:The phase 3 KEYNOTE-590 study. Ann Oncol 31:S1192-S1193,2020
- 10) Hironaka S, Tsubosa Y, Mizusawa J, et al:Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esopha-geal cancer(JCOG0807). Cancer Sci 105:1189-1195,2014
- 11) 日本食道学会, 日本臨床腫瘍学会, 日本癌治療学会:食道癌に対するオキサリプラチンの使用について. 2019
- 12) Kudo T, Hamamoto Y, Kato K, et al:Nivolumab treatment for oesophageal squamous-cell carci-noma:an open-label, multicentre, phase 2 trial. Lancet Oncol 18:631-639,2017
- 13) Kato K, Cho BC, Takahashi M, et al:Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy(AT-TRACTION-3):a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:1506-1517,2019
- 14) Kojima T, Shah MA, Muro K, et al:Randomized Phase III KEYNOTE-181 Study of Pembrolizum-ab Versus Chemotherapy in Advanced Esopha-geal Cancer. J Clin Oncol 38:4138-4148,2020
- 15) Kato K, Tahara M, Hironaka S, et al:A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in pa-tients who had previously received platinum-based chemotherapy. Cancer Chemother Phar-macol 67:1265-1272,2011
- 16) Chau I, Doki Y, Ajani JA, et al:Nivolumab(NIVO)plus ipilimumab(IPI)or NIVO plus chemotherapy(chemo)versus chemo as first-line(1L)treatment for advanced esophageal squamous cell carcinoma(ESCC):First results of the CheckMate 648 study. J Clin Oncol 39,2021
- 17) Kelly RJ, Ajani JA, Kuzdzal J, et al:Adjuvant Nivolumab in Resected Esophageal or Gastro-esophageal Junction Cancer. N Engl J Med 384:1191-1203,2021
